Evaluation of Spectra Optia RBC Exchange in Sickle Cell Patients (ESSENTIAL)
This study is currently recruiting participants.
Verified March 2013 by Terumo BCT
Sponsor:
Terumo BCT
Information provided by (Responsible Party):
Terumo BCT
ClinicalTrials.gov Identifier:
NCT01736657
First received: November 27, 2012
Last updated: March 7, 2013
Last verified: March 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to evaluate the performance of the Spectra Optia system red blood cell exchange (RBCx) protocols (exchange and depletion/exchange) in study participants with sickle cell disease.
| Condition | Intervention |
|---|---|
|
Sickle Cell Disease |
Device: Red blood cell exchange for patients with sickle cell disease |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Evaluation of the Spectra Optia Apheresis Red Blood Cell Exchange Protocol in Patients With Sickle Cell Disease. |
Resource links provided by NLM:
Genetics Home Reference related topics:
sickle cell disease
MedlinePlus related topics:
Sickle Cell Anemia
U.S. FDA Resources
Further study details as provided by Terumo BCT:
Primary Outcome Measures:
- Evaluate the mean FCRa and FCRp [ Time Frame: Six months ] [ Designated as safety issue: No ]The primary endpoint will evaluate the mean ratio of the Actual Fraction of Cells Remaining (FCRa; as measured by Post-Procedure % HbS) to the Predicted Fraction of Cells Remaining (FCRp; as predicted by the Spectra Optia system FCR algorithm), in the Evaluable subject population.
Secondary Outcome Measures:
- Procedural Success of the Spectra Optia system in the Evaluable population [ Time Frame: Six months ] [ Designated as safety issue: No ]
- Spectra Optia system's ability to achieve the desired final hematocrit in the Evaluable population [ Time Frame: Six months ] [ Designated as safety issue: No ]
- Device-related serious adverse events (SAE) in the Full Analysis Set [ Time Frame: Six months ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 60 |
| Study Start Date: | November 2012 |
| Estimated Study Completion Date: | May 2013 |
| Estimated Primary Completion Date: | March 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Red blood cell exchange for patients with sickle cell disease |
Device: Red blood cell exchange for patients with sickle cell disease
The purpose of this study is to evaluate the performance of the Spectra Optia system.
|
Eligibility| Ages Eligible for Study: | 12 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- At least 12 years old
- Enrolled in a program of regular RBCx to prevent symptoms/complications of sickle cell disease (SCD) or Initiating a program of regular RBCx or Receiving RBCx as a pre-surgical procedure.
- Medically stable
- Previous documentation of diagnosis by hemoglobin electrophoresis of a type of sickle cell disorder requiring RBCx.
- Sufficient vascular access to accommodate the RBCx procedure as determined by the apheresis technician performing the procedure or phlebotomist responsible for obtaining intravenous access.
- Availability of sickle trait negative, leukoreduced, ABO, Rh (D) compatible, unexpired replacement blood. See Glossary for definition of replacement blood.
- Able to commit to the study follow-up schedule.
- Agree to report adverse events (AEs) during the required reporting period.
Exclusion Criteria:
- Inability to obtain informed consent/assent from patient, or permission from parent or guardian.
- Pregnancy (negative serum pregnancy test required for females of childbearing potential).
- Life expectancy is fewer than 30 days from time of procedure.
- Incarcerated or a ward of the court.
- Refusal of blood products.
- Failure to comply with site standard requirements for cessation of medications (e.g., ACE inhibitors) that interfere with or increase risk of RBCx procedures.
- History of drug or alcohol abuse that, in the opinion of the investigator, could affect the ability of the patient to comply with the study requirements Inability to comply with the protocol in the opinion of the investigator.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01736657
Contacts
| Contact: Ray P Goodrich, PhD | 303-205-2680 | ray.goodrich@terumobct.com |
| Contact: Diane Rhodes | 303-231-4088 | diane.rhodes@terumobct.com |
Locations
| United States, Alabama | |
| Children's of Alabama | Recruiting |
| Birmingham, Alabama, United States, 35233 | |
| Contact: Thomas Howard, MD 205-410-5644 THoward@peds.uab.edu | |
| Contact: Jeffery Lebensburger Lebensburger@peds.uab.edu | |
| Principal Investigator: Thomas Howard, MD | |
| Sub-Investigator: Jeffery Lebensburger | |
| United States, California | |
| Children's Hospital and Research Center at Oakland | Recruiting |
| Oakland, California, United States, 94609 | |
| Contact: Keith Quirolo, MD 510-428-3885 ext 2517 KQuirolo@mail.cho.org | |
| Contact: Lynne Neumayr (510) 428-3698 LNeumayr@mail.cho.org | |
| Principal Investigator: Keith Quirolo, MD | |
| Sub-Investigator: Lynne Neumayr | |
| United States, Colorado | |
| University of Colorado at Denver | Recruiting |
| Aurora, Colorado, United States, 80045 | |
| Contact: Kathryn Hassell, MD 720-848-0300 Kathryn.Hassell@ucdenver.edu | |
| Contact: Rodabe Amaria rodabe.amaria@ucdenver.edu | |
| Principal Investigator: Kathryn Hassell, MD | |
| Sub-Investigator: Rodabe Amaria | |
| United States, Kentucky | |
| Kosair Children's Hospital | Recruiting |
| Louisville, Kentucky, United States, 40202 | |
| Contact: Salvatore Bertolone, MD 502-852-8465 sjbert01@louisville.edu | |
| Principal Investigator: Salvatore Bertolone, MD | |
| United States, Maryland | |
| Johns Hopkins Medical | Recruiting |
| Baltimore, Maryland, United States, 21205 | |
| Contact: Karen King, MD 410-614-0205 kking@jhmi.edu | |
| Contact: Rosemary Case casero@jhmi.edu | |
| Principal Investigator: Karen King, MD | |
| Sub-Investigator: Rosemary Case | |
Sponsors and Collaborators
Terumo BCT
Investigators
| Principal Investigator: | Keith Quirolo, MD | Children's Hospital and Research Center at Oakland |
More Information
No publications provided
| Responsible Party: | Terumo BCT |
| ClinicalTrials.gov Identifier: | NCT01736657 History of Changes |
| Other Study ID Numbers: | CTS-5001 |
| Study First Received: | November 27, 2012 |
| Last Updated: | March 7, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Anemia, Sickle Cell Anemia, Hemolytic, Congenital Anemia, Hemolytic Anemia |
Hematologic Diseases Hemoglobinopathies Genetic Diseases, Inborn |
ClinicalTrials.gov processed this record on May 22, 2013